Anthony Manning Net Worth

The estimated Net Worth of Anthony M. Manning is at least $3.9 Million dollars as of 13 August 2020. Anthony Manning owns over 403 units of Palatin Technologies stock worth over $18,273 and over the last 7 years he sold PTN stock worth over $3,883,815. In addition, he makes $0 as Independent Director at Palatin Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Anthony Manning PTN stock SEC Form 4 insiders trading

Anthony has made over 31 trades of the Palatin Technologies stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 403 units of PTN stock worth $11,812 on 13 August 2020.

The largest trade he's ever made was exercising 51,445 units of Palatin Technologies stock on 24 December 2019 worth over $642,548. On average, Anthony trades about 5,951 units every 14 days since 2017. As of 13 August 2020 he still owns at least 12,778 units of Palatin Technologies stock.

You can see the complete history of Anthony Manning stock trades at the bottom of the page.

Anthony Manning biography

Dr. Anthony M. Manning Ph.D. serves as Independent Director of the Company. Since 2013, Dr. Manning has been senior vice president of research, and since 2018 chief scientific officer, at Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing innovative therapeutics for rare immune-related diseases. From 2011 to 2013, he was senior vice president of research and development at Aileron Therapeutics, Inc., a publicly traded biopharmaceutical company developing stapled peptide therapeutics for cancers and other diseases. From 2007 to 2011, he was vice president and head of inflammation and autoimmune diseases research at Biogen, Inc., a publicly traded biopharmaceutical company developing medicines for neurological and neurodegenerative conditions. From 2002 to 2007, he was vice president and global therapy area head for Inflammation, Autoimmunity and Transplantation Research at Roche Pharmaceuticals, the pharmaceutical division of Roche Holding AG, and from 2000 to 2002 he was vice president of Pharmacia, a global pharmaceutical company acquired by Pfizer in 2002. Dr. Manning received his Ph.D., M.Sc. and B.Sc. from the University of Otago, Dunedin, New Zealand.

How old is Anthony Manning?

Anthony Manning is 58, he's been the Independent Director of Palatin Technologies since 2017. There are 10 older and 1 younger executives at Palatin Technologies. The oldest executive at Palatin Technologies Inc. is Robert deVeer, 74, who is the Independent Director.

What's Anthony Manning's mailing address?

Anthony's mailing address filed with the SEC is PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Palatin Technologies

Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... und Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.

What does Palatin Technologies do?

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy

Complete history of Anthony Manning stock trades at Momenta Pharmaceuticals und Palatin Technologies

Palatin Technologies executives and stock owners

Palatin Technologies executives and other stock owners filed with the SEC include:

• Carl Spana,
  President, Chief Executive Officer, Director
• stephen Wills,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
• Dr. Carl Spana Ph.D.,
  Co-Founder, Pres, CEO & Director
• Stephen T. Wills CPA, CPA, MST,
  CFO, COO, Exec. VP, Treasurer & Sec.
• Angela Rossetti,
  Independent Director
• Arlene Morris,
  Independent Director
• Anthony Manning,
  Independent Director
• Joseph Hull,
  Independent Director
• Alan Dunton,
  Independent Director
• Robert deVeer,
  Independent Director
• John Prendergast,
  Independent Chairman of the Board
• Robert Jordan,
  Sr. VP of Program Operations
• John Dodd Ph.D.,
  Sr. VP of Preclinical Devel.
• James E. Hattersley,
  Sr. VP of Bus. Devel.
• Dr. Michael B. Raizman M.D.,
  Chief Medical Officer
• Stephen A. Slusher Esq.,
  Chief Legal Officer
• Burns McClellan,
  VP of Investor Relations
• Zola P Horovitz,
  Director
• Robert I Taber,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Austin W & Greenhouse David...,
  10% owner
• Errol B Desouza,
  Director
• Trevor Hallam,
  Exec. VP Res. & Dev.
• Perry B Molinoff,
  Exec. VP Research and Devel.
• Investments Lpproquest Asso...,
  
• Joseph Edelman,
  10% owner